Literature DB >> 8687106

Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function.

S M Hewitt1, G F Saunders.   

Abstract

The Wilms' tumor gene WT1 encodes a zinc-finger transcription factor that functions as a tumor suppressor gene and repress transcription of a number of growth factors and proto-oncogenes. In the developing kidney, WT1 expression peaks at the onset of the mesenchyme-to-epithelium transition and is required for epithelial differentiation. WT1 mRNA undergoes alternative splicing at two sites, resulting in four mRNA species and proteins expressed in constant ratios. The first alternative splice results in the presence or absence of exon 5, which is 51 nucleotides long and encodes 17 amino acids between the amino-terminal, proline-rich transcriptional repression domain and the carboxy-terminal DNA-binding zinc-fingers. We used cell-proliferation assays to determine the effect of exon 5 on WT1 function. Isoforms of WT1 without exon S repressed cell growth. WT1 isoforms with exon 5 slowed cell growth to a lesser extent but resulted in altered cellular morphology. These results provide evidence that WT1 splice isoforms differentially regulate cell proliferation and initiate the mesenchyme-to-epithelium transition during metanephric development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687106

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  AHR regulates WT1 genetic programming during murine nephrogenesis.

Authors:  M Hadi Falahatpisheh; Adrian Nanez; Kenneth S Ramos
Journal:  Mol Med       Date:  2011-08-18       Impact factor: 6.354

2.  WT1 expression is increased in primary fibroblasts derived from Dupuytren's disease tissues.

Authors:  Justin Crawford; Christina Raykha; Daevina Charles; Bing Siang Gan; David B O'Gorman
Journal:  J Cell Commun Signal       Date:  2015-06-30       Impact factor: 5.782

3.  A mammal-specific exon of WT1 is not required for development or fertility.

Authors:  Thomas A Natoli; Alice McDonald; Julia A Alberta; Mary E Taglienti; David E Housman; Jordan A Kreidberg
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

4.  Investigation of FJ 194940.1 gene alternative splicing in colon cancer and its association with clinicopathological parameters.

Authors:  Malwina Bartczak-Tomczyk; Aleksandra Sałagacka; Marek Mirowski; Ewa Balcerczak
Journal:  Exp Ther Med       Date:  2011-11-09       Impact factor: 2.447

Review 5.  Regulation of gene expression by WT1 in development and tumorigenesis.

Authors:  Leif W Ellisen
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.